Last Updated: 13 Oct 2024
Executive Summary
In8bio Inc. (INAB) is a clinical-stage biotechnology company focused on developing new therapies for the treatment of cancers, including solid tumors using genetically modified, autologous, allogeneic gamma-delta T cells. The company's latest stock price is $0.23. Analysts rate INAB as a Buy, with a target price of $7.38.
Company Overview
In8bio Inc. is headquartered in New York, New York. The company's mission is to develop and commercialize novel immunotherapies for the treatment of cancer. In8bio's lead product candidate, INB-401, is a genetically modified, autologous gamma-delta T cell therapy that targets the GD2 antigen. INB-401 is currently in Phase 2 clinical trials for the treatment of neuroblastoma and other GD2-expressing tumors.
Fundamental Analysis
In8bio Inc. is a pre-revenue company, so it does not have any financial metrics to analyze. However, the company has a strong cash position of $163.3 million as of June 30, 2024. This gives In8bio the financial resources to continue to develop its pipeline of product candidates.
Technical Analysis
In8bio Inc.'s stock price has been in a downtrend since early 2023. The stock is currently trading below its 50-day and 200-day moving averages. The relative strength index (RSI) is also below 50, indicating that the stock is oversold.
Short Term Outlook
In the short term, In8bio Inc.'s stock price is likely to continue to trade in a range. The stock could see some upside if the company announces positive clinical data for INB-401. However, the stock could also see downside if the company announces negative clinical data or if the overall market continues to decline.
Long Term Outlook
In the long term, In8bio Inc. has the potential to be a successful company. The company's lead product candidate, INB-401, has shown promising results in clinical trials. If INB-401 is approved by the FDA, it could be a major commercial success. In8bio also has a pipeline of other product candidates that could generate additional revenue in the future.
Analyst Recommendations
Analysts rate In8bio Inc. as a Buy. The average analyst target price is $7.38. Analysts believe that In8bio has the potential to be a successful company, and they recommend that investors buy the stock at current levels.
